Gilead Expands Liver Disease Pipeline by Purchasing Phenex’s Farnesoid X Receptor Programme
By Heather Cartwright
Pharma Deals Review: Vol 2015 Issue 1 (Table of Contents)
Published: 22 Jan-2015
DOI: 10.3833/pdr.v2015.i1.2089 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a deal worth up to US$470 M, Gilead Sciences has agreed to acquirePhenex Pharmaceuticals’ development programme of farnesoid X receptor (FXR) agonistsfor non-alcoholic steatohepatitis (NASH) and other liver diseases, including its Phase II asset Px-104...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS